May 22, 2026
avatar-angus-chen
Cancer Reporter

Hi everyone. I’m on my way back to California and will be heading to ASCO in Chicago next week. The travel continues, so today we’re going to take a very brief look at the companies using dogs to detect cancer. Stories where people felt like their pets could “sense” their cancer before they were diagnosed seem relatively common, and it seems at least plausible that dogs, with their highly sensitive olfactory systems, might be picking up on something.

Well, companies like SpotitEarly and Dognosis have been trying to put that into practice. These companies have been publishing papers in the literature for some years now and, basically, their argument for this detection method is that dogs can detect volatile organic compounds that might signify if someone has cancer. Then, both companies use AI to pick up on signals in the dogs’ behavior or other certain markers (like signals from a doggy EEG cap) to try to see if the dog has detected something. The dogs reportedly can detect cancer with an accuracy rate in the mid 90%, according to the companies. They’re obviously very cute, too.

If it really works, well that will be very interesting. The companies have said that one issue they are faced with is scaling.


Yale Rosen/ Wikimedia Commons

STAT+ | Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows

Phase 3 trial data on sacituzumab tirumotecan, or sac-TMT, showed tumor progression risk fell by 65%. The drug, developed in China, is licensed to Merck.

By Adam Feuerstein


STAT+ | Acting head of NIH’s infectious disease institute reported to have stepped down

Exit of Jeffery Taubenberger, director of NIAID, would widen leadership vacuum at nation’s top biomedical research agency.

By Helen Branswell and Anil Oza


STAT+ | OpenEvidence makes its pitch to hospitals. ‘We’re not crazy monsters’

OpenEvidence CTO Zachary Ziegler said, at the STAT Breakthrough Summit West, that the company is looking beyond its massive user base of physicians. 

By Katie Palmer



Mass General Brigham

Mass General Brigham says it is saving more lives. Some doctors aren’t so sure.

BOSTON — In a meeting for Mass General Brigham doctors in November 2024, Dr. Giles Boland, president of Brigham and Women’s Hospital, laid out the vision for becoming the best in the country. Thanks to a corporate merging of its hospitals, he said, the system was well on its way, making progress on delivering the best outcomes possible for patients, including its most important job — keeping people alive.

Boland specifically pointed to MGB’s strides on a metric called observed-to-expected mortality, which compares how many people died while admitted to the hospital, versus how many were projected to die, given their levels of illness.

By Jessica Bartlett — Boston Globe


More around STAT

In other news

  • The China question is tearing biotech apart, STAT
  • Weight-loss drugs may have a surprising side effect: stalling cancer, Wall Street Journal
  • AstraZeneca breast cancer drug gets EU nod after FDA disappointment, Bloomberg

Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Cancer Briefing? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.